Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.

Literature DB >> 30684252

Comparison of neutropenia profiles in different treatment protocols for acute myeloid leukemia using the D-index.

Yasufumi Kawasaki¹, Shun-Ichi Kimura², Hirofumi Nakano¹, Kiyomi Mashima¹, Yuya Shirato¹, Shin-Ichiro Kawaguchi¹, Yumiko Toda¹, Shin-Ichi Ochi¹, Takashi Nagayama¹, Daisuke Minakata¹, Ryoko Yamasaki¹, Kaoru Morita¹, Masahiro Ashizawa¹, Chihiro Yamamoto¹, Kaoru Hatano¹, Kazuya Sato¹, Iekuni Oh¹, Shin-Ichiro Fujiwara¹, Ken Ohmine¹, Shinichi Kako², Kazuo Muroi¹, Yoshinobu Kanda^3,4.

Abstract

Neutropenia is a major risk factor for opportunistic infections in patients with acute myeloid leukemia (AML) who undergo chemotherapy. In the present study, we retrospectively compared the D-index, which reflects both the depth and duration of neutropenia, between two different chemotherapy regimens for AML. Sixty-seven patients with AML were included: 37 received an induction regimen of daunorubicin (DNR) and cytarabine followed by consolidation therapies consisting of standard-dose cytarabine (SDAC) and other antineoplastic agents; the remaining 30 received idarubicin (IDR) and cytarabine as remission induction therapy followed by high-dose cytarabine (HDAC). The duration of neutropenia was shorter, but the D-index was higher, with IDR than with DNR. The total D-index during the entire consolidation therapies was significantly higher with SDAC than with HDAC. In conclusion, the neutropenia profile differs between treatment regimens, and thus, physicians should plan the management of infectious complications according to the neutropenia profile for each regimen.

Entities: Chemical Disease Gene Species

Keywords: Acute myeloid leukemia; Anthracycline; D-index; High-dose cytarabine; Neutropenia

Mesh：

Substances：

Year: 2019 PMID： 30684252 DOI： 10.1007/s12185-019-02593-2

Source DB: PubMed Journal: Int J Hematol ISSN： 0925-5710 Impact factor: 2.490

10 in total

1. Retrospective evaluation of the area over the neutrophil curve index to predict early infection in hematopoietic stem cell transplantation recipients.

Authors: Shun-Ichi Kimura; Kumi Oshima; Ken Sato; Miki Sato; Kiriko Terasako; Hideki Nakasone; Misato Kikuchi; Shinya Okuda; Shinichi Kako; Rie Yamazaki; Yukie Tanaka; Aki Tanihara; Junji Nishida; Yoshinobu Kanda
Journal: Biol Blood Marrow Transplant Date: 2010-05-10 Impact factor: 5.742

2. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study.

Authors: Shuichi Miyawaki; Shigeki Ohtake; Shin Fujisawa; Hitoshi Kiyoi; Katsuji Shinagawa; Noriko Usui; Toru Sakura; Koichi Miyamura; Chiaki Nakaseko; Yasushi Miyazaki; Atsushi Fujieda; Tadashi Nagai; Takahisa Yamane; Masafumi Taniwaki; Masatomo Takahashi; Fumiharu Yagasaki; Yukihiko Kimura; Norio Asou; Hisashi Sakamaki; Hiroshi Handa; Sumihisa Honda; Kazunori Ohnishi; Tomoki Naoe; Ryuzo Ohno
Journal: Blood Date: 2010-12-29 Impact factor: 22.113

3. D-index dose not predict the development of pulmonary infection in acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine.

Authors: Shun-ichi Kimura; Hidenori Wada; Yuko Ishihara; Koji Kawamura; Kana Sakamoto; Ryoko Yamasaki; Masahiro Ashizawa; Tomohito Machishima; Miki Sato; Kiriko Terasako; Hideki Nakasone; Misato Kikuchi; Shinya Okuda; Shinichi Kako; Junya Kanda; Rie Yamazaki; Aki Tanihara; Junji Nishida; Yoshinobu Kanda
Journal: Hematology Date: 2013-11-25 Impact factor: 2.269

4. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal: Clin Infect Dis Date: 2011-02-15 Impact factor: 9.079

5. Impact of the D-index deduced from duration and intensity of neutropenia following chemotherapy on the risk of invasive fungal infection in pediatric acute myeloid leukemia.

Authors: Hirozumi Sano; Ryoji Kobayashi; Daisuke Suzuki; Daiki Hori; Kenji Kishimoto; Kunihiko Kobayashi
Journal: Int J Hematol Date: 2018-03-21 Impact factor: 2.490

6. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.

Authors: Shigeki Ohtake; Shuichi Miyawaki; Hiroyuki Fujita; Hitoshi Kiyoi; Katsuji Shinagawa; Noriko Usui; Hirokazu Okumura; Koichi Miyamura; Chiaki Nakaseko; Yasushi Miyazaki; Atsushi Fujieda; Tadashi Nagai; Takahisa Yamane; Masafumi Taniwaki; Masatomo Takahashi; Fumiharu Yagasaki; Yukihiko Kimura; Norio Asou; Hisashi Sakamaki; Hiroshi Handa; Sumihisa Honda; Kazunori Ohnishi; Tomoki Naoe; Ryuzo Ohno
Journal: Blood Date: 2010-08-06 Impact factor: 22.113

7. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve.

Authors: Rodrigo D Portugal; Marcia Garnica; Marcio Nucci
Journal: J Clin Oncol Date: 2009-07-13 Impact factor: 44.544

1 in total

1. c-D-index at day 11 can predict febrile neutropenia during chemotherapy in acute myeloid leukemia.

Authors: Hiroyuki Kubo; Osamu Imataki; Yukiko Hamasaki Kubo; Makiko Uemura
Journal: PLoS One Date: 2022-03-17 Impact factor: 3.240